Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

INTRODUCTION: Imeglimin, a glucose‐lowering agent targeting mitochondrial bioenergetics, decreases reactive oxygen species (ROS) overproduction and improves glucose homeostasis. We investigated whether this is associated with protective effects on metabolic syndrome‐related left ventricular (LV) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lachaux, Marianne, Soulié, Matthieu, Hamzaoui, Mouad, Bailly, Anaëlle, Nicol, Lionel, Rémy‐Jouet, Isabelle, Renet, Sylvanie, Vendeville, Cathy, Gluais‐Dagorn, Pascale, Hallakou‐Bozec, Sophie, Monteil, Christelle, Richard, Vincent, Mulder, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375119/
https://www.ncbi.nlm.nih.gov/pubmed/32704553
http://dx.doi.org/10.1002/edm2.128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375119/
https://www.ncbi.nlm.nih.gov/pubmed/32704553
http://dx.doi.org/10.1002/edm2.128

Ejemplares similares